Drug Profile
HPN 536
Alternative Names: Mesothelin/CD3-specific TriTAC; HPN-536; MSLN TriTACLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Harpoon Therapeutics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 11 Mar 2024 Harpoon Therapeutics has been acquired by Merck & Co
- 09 Aug 2023 Discontinued - Phase-I/II for Mesothelioma (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 09 Aug 2023 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)